Zhihua Kang

1.1k citations
34 papers · 782 indexed · h-index 16
Topics
Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers)Hedgehog Signaling Pathway Studies (6 papers)Cancer and Skin Lesions (6 papers)
Partner nations
ChinaUnited StatesSweden

In The Last Decade

Zhihua Kang

33 papers receiving 775 citations

Peers

Zhihua Kang
Comparison fields: 5 of 84
  • Molecular Biology 372
  • Dermatology 168
  • Epidemiology 141
  • Rheumatology 123
  • Oncology 116
Replace Yi Fritz with:
Yi Fritz United States
Elisabetta Agea Italy
Antigoni Triantafyllopoulou United States
Xueyan Peng United States
Giampiero Girolomoni Italy
Samuel J. Balin United States
Günter Michel Germany
Maik Voskort Germany
T.J. Stoof Netherlands
Yoji Takano Japan
Zhihua Kang relative to Yi Fritz United States Yi Fritz's profile →
Citations per field
00.5×2.7×
Yi Fritz · 1×
Citations per year

Countries citing papers authored by Zhihua Kang

Since Specialization
Citations

This map shows the geographic impact of Zhihua Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhihua Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhihua Kang more than expected).

Fields of papers citing papers by Zhihua Kang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhihua Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhihua Kang. The network helps show where Zhihua Kang may publish in the future.

Co-authorship network of co-authors of Zhihua Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Zhihua Kang. A scholar is included among the top collaborators of Zhihua Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhihua Kang. Zhihua Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 3
3 1
4 7
5 8
6 55
7 23
8 15
9 28
10 37
11 6
12
Clinical and pathological characteristics of extramammary Paget's disease: report of 246 Chinese male patients.
43
13 8
14 8
15 5
16 38
17 5
18 5
19 14
20 11

About Zhihua Kang

Zhihua Kang is a scholar working on Dermatology, Genetics and Rheumatology, having authored 34 papers that have together received 782 indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers), Hedgehog Signaling Pathway Studies (6 papers) and Cancer and Skin Lesions (6 papers). The work is most often cited by research in Dermatology (168 citations), Rheumatology (123 citations) and Microbiology (41 citations). Zhihua Kang has collaborated with scholars based in China, United States and Sweden. Frequent co-authors include Ming Guan, Zhiyuan Wu, Xinju Zhang, Xiao Xu, Bing Xia, Zhiyuan Shen, Tzeh Keong Foo, Shibao Li, Pan Fu and Feng Xu. Their work appears in journals such as Nature Communications, PLoS ONE and Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026